HMC Capital Ltd (ASX: HMC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
HMC Capital Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
HMC Capital Ltd (ASX: HMC)
Latest News
Dividend Investing
Guess which ASX stock could pay a 9% dividend yield in 2027
Share Fallers
Why Bougainville Copper, Brainchip, Challenger, and HMC Capital shares are falling today
Dividend Investing
1 ASX dividend stock down 64% I'd buy right now
Share Gainers
Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Investing Strategies
I would invest $5,000 in these ASX 300 shares in January
Share Fallers
5 worst ASX All Ords shares of 2025, and why brokers rate 4 of them a buy
Share Fallers
These were the worst performing ASX 200 shares in 2025
Share Gainers
Here are the top 10 ASX 200 shares today
Share Fallers
Why Domino's, HMC Capital, Regis Healthcare, and WiseTech shares are falling today
Share Market News
5 things to watch on the ASX 200 on Monday
Frequently Asked Questions
-
Yes, HMC Capital has historically paid largely fully franked shareholder dividends twice a year.
-
HMC Capital generally pays its shareholder dividends in April and October.
-
HMC Capital Ltd listed on the ASX on 14 October 2019.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 26 Aug 2025 | $0.0600 | 0.00% | Final | 30 Sep 2025 |
| 25 Feb 2025 | $0.0600 | 100.00% | Interim | 01 Apr 2025 |
| 27 Aug 2024 | $0.0600 | 70.00% | Final | 02 Oct 2024 |
| 26 Feb 2024 | $0.0600 | 0.00% | Interim | 02 Apr 2024 |
| 29 Aug 2023 | $0.0600 | 10.00% | Final | 04 Oct 2023 |
| 01 Mar 2023 | $0.0600 | 100.00% | Interim | 06 Apr 2023 |
| 01 Sep 2022 | $0.0600 | 100.00% | Final | 07 Oct 2022 |
| 01 Mar 2022 | $0.0600 | 100.00% | Interim | 07 Apr 2022 |
| 02 Sep 2021 | $0.0600 | 50.00% | Final | 01 Oct 2021 |
| 02 Mar 2021 | $0.0600 | 100.00% | Interim | 17 Mar 2021 |
| 03 Sep 2020 | $0.0750 | 100.00% | Final | 18 Sep 2020 |
| 04 Mar 2020 | $0.0450 | 100.00% | Interim | 19 Mar 2020 |
HMC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About HMC Capital Ltd
HMC Capital Ltd (ASX: HMC) is an ASX-listed property company focusing on ownership, development, and management of real estate assets. HMC currently has more than $7.5 billion of assets under management (AUM) across real estate and private equity strategies. It is also looking to bolster opportunities in energy transition, value-add infrastructure, and private credit. Two listed real estate investment trusts (REITs) operate under the company structure as well as several unlisted funds.
HMC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Feb 2026 | $3.06 | $-0.07 | -2.24% | 2,007,927 | $3.05 | $3.11 | $3.02 |
| 19 Feb 2026 | $3.13 | $-0.02 | -0.63% | 1,990,417 | $3.15 | $3.17 | $3.00 |
| 18 Feb 2026 | $3.15 | $0.09 | 2.94% | 3,695,288 | $3.13 | $3.18 | $3.08 |
| 17 Feb 2026 | $3.06 | $-0.07 | -2.24% | 2,358,586 | $3.09 | $3.10 | $3.02 |
| 16 Feb 2026 | $3.13 | $0.02 | 0.64% | 2,315,451 | $3.13 | $3.18 | $3.05 |
| 13 Feb 2026 | $3.11 | $-0.21 | -6.33% | 2,813,945 | $3.29 | $3.29 | $3.10 |
| 12 Feb 2026 | $3.32 | $-0.28 | -7.78% | 3,089,416 | $3.62 | $3.63 | $3.30 |
| 11 Feb 2026 | $3.60 | $-0.14 | -3.74% | 1,890,500 | $3.74 | $3.75 | $3.59 |
| 10 Feb 2026 | $3.74 | $0.02 | 0.54% | 2,450,908 | $3.75 | $3.91 | $3.68 |
| 09 Feb 2026 | $3.72 | $-0.20 | -5.10% | 8,337,515 | $4.02 | $4.09 | $3.69 |
| 06 Feb 2026 | $3.92 | $-0.11 | -2.73% | 14,933,436 | $4.10 | $4.34 | $3.73 |
| 05 Feb 2026 | $4.03 | $0.00 | 0.00% | 1,839,382 | $4.03 | $4.10 | $3.98 |
| 04 Feb 2026 | $4.03 | $-0.22 | -5.18% | 1,255,497 | $4.25 | $4.26 | $4.02 |
| 03 Feb 2026 | $4.25 | $0.06 | 1.43% | 1,079,912 | $4.22 | $4.27 | $4.13 |
| 02 Feb 2026 | $4.19 | $-0.01 | -0.24% | 827,779 | $4.15 | $4.26 | $4.12 |
| 30 Jan 2026 | $4.20 | $-0.02 | -0.47% | 1,940,912 | $4.20 | $4.39 | $4.12 |
| 29 Jan 2026 | $4.22 | $0.05 | 1.20% | 1,013,383 | $4.17 | $4.22 | $4.07 |
| 28 Jan 2026 | $4.17 | $0.04 | 0.97% | 2,198,291 | $4.27 | $4.36 | $4.13 |
| 27 Jan 2026 | $4.13 | $-0.19 | -4.40% | 1,694,300 | $4.32 | $4.32 | $4.00 |
| 23 Jan 2026 | $4.32 | $0.16 | 3.85% | 620,367 | $4.16 | $4.35 | $4.16 |
| 22 Jan 2026 | $4.16 | $0.11 | 2.72% | 1,188,302 | $4.13 | $4.22 | $4.08 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Nov 2025 | Christopher Roberts | Issued | 17,120 | $60,776 |
Director remuneration. 17,120 rights
|
| 27 Nov 2025 | Gregory (Greg) Hayes | Issued | 15,692 | $55,706 |
Director remuneration. 21,393 rights
|
| 27 Nov 2025 | Fiona Pak-Poy | Issued | 15,692 | $55,706 |
Director remuneration. 15,692 rights
|
| 27 Nov 2025 | David Di Pilla | Issued | 595,924 | $2,115,530 |
Issue of securities. 1,639,348 performance rights
|
| 27 Nov 2025 | Christopher Saxon | Issued | 35,666 | $126,614 |
Director remuneration. 35,666 rights
|
| 27 Nov 2025 | Kelly O'Dwyer | Issued | 21,400 | $75,970 |
Director remuneration. 21,400 rights
|
| 27 Nov 2025 | Susan Roberts | Issued | 19,972 | $70,900 |
Director remuneration. 19,972 rights
|
| 21 Nov 2025 | Kelly O'Dwyer | Buy | 32,959 | $104,761 |
On-market trade. 1000 Prior Holding
|
| 30 Sep 2025 | David Di Pilla | Expiry | 179,616 | $571,178 |
As advised by the company. Lapsed, 10,43,424 Rights
|
| 05 Sep 2025 | David Di Pilla | Buy | 367,783 | $1,316,663 |
On-market trade.
|
| 04 Sep 2025 | David Di Pilla | Buy | 200,120 | $684,410 |
On-market trade.
|
| 20 Aug 2025 | David Di Pilla | Buy | 1,346,181 | $5,021,913 |
On-market trade.
|
| 20 Aug 2025 | Christopher Saxon | Exercise | 8,036 | $30,938 |
Conversion of securities.
|
| 20 Aug 2025 | Christopher Saxon | Buy | 8,036 | $30,938 |
Conversion of securities.
|
| 20 Aug 2025 | Fiona Pak-Poy | Buy | 3,621 | $13,940 |
Conversion of securities.
|
| 20 Aug 2025 | Fiona Pak-Poy | Exercise | 3,621 | $13,940 |
Conversion of securities.
|
| 20 Aug 2025 | Gregory (Greg) Hayes | Buy | 3,536 | $13,613 |
Conversion of securities.
|
| 20 Aug 2025 | Gregory (Greg) Hayes | Exercise | 3,536 | $13,613 |
Conversion of securities. 5,701 rights
|
| 20 Aug 2025 | Christopher Roberts | Exercise | 3,952 | $15,215 |
Conversion of securities.
|
| 20 Aug 2025 | Christopher Roberts | Buy | 3,952 | $15,215 |
Conversion of securities.
|
| 20 Aug 2025 | Susan Roberts | Buy | 4,500 | $17,325 |
Conversion of securities.
|
| 20 Aug 2025 | Susan Roberts | Exercise | 4,500 | $17,325 |
Conversion of securities.
|
| 20 Aug 2025 | Kelly O'Dwyer | Exercise | 4,179 | $16,089 |
Conversion of securities.
|
| 20 Aug 2025 | Kelly O'Dwyer | Buy | 4,179 | $16,089 |
Conversion of securities.
|
| 22 May 2025 | David Di Pilla | Sell | 10,845,709 | $57,048,429 |
As advised by the company. Distribution of shares to HICT unitholder as part of a transaction under which the unitholder redeemed their units in HICT. As per announcement on 26-05-2025
|
| 09 Apr 2025 | Christopher Roberts | Buy | 66,812 | $311,343 |
As advised by the company. Acquisition of fully paid ordinary shares on market.
|
| 08 Apr 2025 | Christopher Roberts | Buy | 86,812 | $410,620 |
As advised by the company. Acquisition of fully paid ordinary shares on market
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Christopher Graham Roberts | Non-Executive Director | Nov 2024 |
Dr Roberts has over 40 years of experience in the medical device industry serving a number of senior management positions. He was the former CEO of Cochlear from 2004 to 2015 and is presently a member of the Cochlear Foundation Board, Non-Executive Director of HCW Funds Management Limited, HMC Capital Partners Fund 1, Atmo Biosciences Ltd, Centenary Institute of Medical Research and Nutromics Pty Ltd. He was also the Executive Vice President of ResMed from 1992 to 2003, and a director until 2017. He was a former Chair of Research Australia from 2004 to 2010. He is member of the risk committee.
|
| Mr Gregory (Greg) John Hayes | Non-Executive Director | Sep 2019 |
Mr Hayes is currently a Non-Executive Director of Aurrum Holdings Pty Ltd and Secure AI Pty Ltd. Having worked across a range of industries including property, infrastructure, energy and logistics, his skills and experience include strategy, finance, mergers and acquisitions and strategic risk management, in particular in listed companies with global operations. He was previously Chief Financial Officer and Executive Director of Brambles Limited, Chief Executive Officer and Group Managing Director of Tenix Pty Ltd, Chief Financial Officer and later interim Chief Executive Officer of the Australian Gaslight Company, Chief Financial Officer Australia and New Zealand of Westfield Holdings, Executive General Manager, Finance of Southcorp Limited. He is a member of Risk Committee.
|
| Ms Fiona Jane Pak-Poy | Non-Executive Director | Nov 2024 |
Ms Pak Poy is Non-Executive Director of Silicon Quantum Computing Pty Ltd and Kain Lawyers Pty Ltd. She is on the Board of Trustees and Investment Committee for HMC Capital Partners Fund 1 and is a member of the Business Advisory Council for Anacacia Capital. She has over 30 years of experience in a variety of industries, for companies ranging from startups to listed companies, government entities and not-for-profits. She has served on various boards, including, MYOB, Isentia, Novotech, PageUp People, StatePlus and SIRCA (the Securities Research Centre of South-East Asia). She served on the ASIC director Advisory Panel and the Board of Innovation Australia. Previously she was a strategy consultant for the Boston Consulting Group in the US and Australia and was a General Partner in an Australian venture capital fund focused on technology startups. She is Member of the Sustainability Committee.
|
| Mr David Anthony Di Pilla | Chief Executive OfficerExecutive DirectorManaging Director | Oct 2017 |
Mr Pilla led the team that founded the consortium which led to the ultimate establishment HMC Capital in 2016. Since this time, the HMC Group has grown from its initial Masters portfolio to today being a diversified alternative asset manager. He has over 30 years of experience in investment banking, strategic advisory & consulting and corporate leadership as a Director and CEO. During his 20-year investment banking career he was Managing Director of UBS Investment Bank for over 15 years and during this time led some of Australias landmark transactions across corporate M&A, Equity & Debt Capital Markets. Prior to his time at UBS, he reached the position of Vice President, Investment Banking at JP Morgan.
|
| Mr Christopher Saxon | Non-Executive DirectorNon-Executive Chairman | Sep 2019 |
Mr Saxon was, until 2019, a partner with global law firm Baker McKenzie. His practice included large scale mergers and acquisition transactions across a range of sectors, notably energy (gas, electricity, renewable), industrials, infrastructure and mining. He has been ranked as one of Australias foremost project and M&A lawyers and has been lead adviser on government restructuring transactions and privatisations, major trade sales and infrastructure projects. He served as Chair of Baker McKenzie Australia for five years (2012-2017) and held numerous leadership roles within the firm.
|
| Hon Kelly Megan O'Dwyer | Non-Executive Director | Nov 2020 |
Hon O Dwyer is a Non-Executive Director of EQT Holdings Limited, HealthCo Healthcare and Wellness REIT, DigiCo Infrastructure REIT, Barrenjoey Capital Partners Group Holdings Pty Ltd and the National Reconstruction Fund Corporation. She previously served in the Australian Parliament as a Senior Cabinet Minister holding a number of key economic portfolios including Minister for Jobs and Industrial Relations; Minister for Revenue and Financial Services; Minister for Small Business; and Assistant Treasurer. She also served on the Cabinets Budget Committee (the Expenditure Review Committee) and held the portfolios of Minister for Women; as well as Minister Assisting the Prime Minister with the Public Service. Prior to entering Parliament, she worked in law, government and finance and brings insights across a range of sectors including funds management, superannuation, workplace relations, foreign investment, law and banking. She is Chair of Sustainability Committee, Member of the Risk Committee.
|
| Ms Susan Roberts | Non-Executive Director | Nov 2022 |
Ms Roberts is an experienced director and CEO with over 30 years in the financial services, investment and insurance industries. Her current roles include Chair of Audit for AIG Australia and Teachers Health, and she is a director of Metlife Australia. She has commercial and financial executive experience, including CEO and Managing Director of Lazard Asset Management Pacific, and Director, Strategy at Lend Lease Investment Services. She has previously served as a Non-Executive Director of Maple Brown Abbott and as Chair of the Audit and Risk, and Claims Committee for Zurich Australia Superannuation. Susan was also Chair of the Investor Working Group for the 30% Club in Australia. She is Member of the Sustainability Committee.
|
| Mr Andrew Selim | Company SecretaryGeneral Counsel |
-
|
|
| Andrew Selim | Company SecretaryGeneral Counsel |
-
|
|
| Will McMicking | Group Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 138,856,111 | 33.98% |
| Home Investment Consortium Trust | 79,535,204 | 19.47% |
| J P Morgan Nominees Australia Pty Limited | 47,317,554 | 11.58% |
| Citicorp Nominees Pty Limited | 35,847,791 | 8.77% |
| Goat Properties Pty Ltd | 12,853,001 | 3.15% |
| National Nominees Limited | 7,762,252 | 1.90% |
| Aurrum Holdings Pty Ltd | 7,023,606 | 1.72% |
| BNP Paribas Nominees Pty Ltd | 4,719,004 | 1.15% |
| Netwealth Investments Limited | 4,031,608 | 0.99% |
| UBS Nominees Pty Ltd | 3,280,022 | 0.80% |
| BNP Paribas Noms Pty Ltd | 2,484,927 | 0.61% |
| CW Property Nominees Pty Ltd | 2,238,806 | 0.55% |
| BNP Paribas Noms Pty Ltd 1 | 2,089,200 | 0.51% |
| Pacific Custodians Pty Limited | 1,513,230 | 0.37% |
| Aldaoud Pty Ltd | 1,300,000 | 0.32% |
| SG Foundation Investments Pty Ltd | 1,071,014 | 0.26% |
| BNP Paribas Noms Pty Ltd 2 | 989,575 | 0.24% |
| HSBC Custody Nominees (Australia) Limited 1 | 945,553 | 0.23% |
| BNP Paribas Noms Pty Ltd 3 | 868,483 | 0.21% |
| Doux Argent Pty Ltd | 743,301 | 0.18% |